UBT251

InvestigationalMetabolic ResearchWeight & metabolic

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is UBT251?

Novo Nordisk reports that a Phase 1a/2b trial has started for UBT251, an investigational triple agonist. It remains early-stage and has not been established as safe or effective for routine use.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for UBT251 yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingEligibility not established.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.